ITM Power’s 3 director buys after a 70% YTD run

The hydrogen trade has not been a sleepy corner of the market this year. Global electrolyser capacity more than doubled in 2025 to more than 4 GW, and the money has kept moving into the broader energy transition, with BloombergNEF putting 2025 investment at a record $2.3 trillion. That matters for a name like ITM Power plc, because this is a business that sells equipment into a capital cycle, not a consumer brand that can coast on sentiment. When the sector is drawing that much capital, the market is not just buying a product. It is buying a view on policy, project finance, industrial scale-up, and the timing of commercial adoption.

ITM makes proton exchange membrane electrolysers for green hydrogen production. That is the core machine, but the commercial logic around it is what really drives the stock. Revenue depends on whether developers keep moving from interest to orders, whether manufacturing can scale without destroying margins, and whether project sponsors can actually fund and execute the installations. In other words, the equity is a claim on a chain of decisions that starts with policy support and ends with delivered equipment. If any link weakens, the stock can re-rate quickly because the market has already given it credit for a lot of the good news.

The share price tells you how much optimism is already embedded. ITM was trading around 106 to 109 GBX in mid-August 2026, after year-to-date gains above 70 percent. That kind of move changes the burden of proof. A stock that has already outrun the index is no longer being judged on whether the theme is real. It is being judged on whether the company can keep turning sector enthusiasm into actual operating milestones. That is why the insider filing matters here, but only as part of the mechanism, not as a standalone signal.

The business is still a project-cycle story, not a slogan

ITM does not live or die on one headline. It lives on the cadence of project awards, manufacturing scale, and whether customers move from interest to purchase orders. That is the right frame because the company is not selling a recurring subscription or a commodity with a daily spot price. It is selling complex industrial equipment into projects that can be delayed, resized, or repriced. The stock therefore responds not just to sector enthusiasm, but to evidence that the pipeline is becoming tangible business.

That is why the July 2026 award of a £46.5 million DESNZ grant matters, and why the earlier £40 million investment commitment from Great British Energy matters too. Those are not abstract endorsements. They are capital and policy support aimed at scaling manufacturing. For a company in this part of the hydrogen stack, manufacturing scale is not a side issue. It is the bridge between being a technology developer and being a supplier that can meet project demand at industrial volume. Without that bridge, even a strong order narrative can remain fragile.

The company also said on 4 August 2026 that it delivered first hydrogen from the GET H2 Nukleus project in Lingen, Germany. For a hydrogen equipment maker, that kind of milestone is not decorative. It shows the installed base is not just a slide deck. It is a live project with molecules moving through it. In this sector, that is the difference between a story stock and a business that can point to operating proof. It also matters because project delivery is what gives customers and policymakers confidence that the technology can move from pilot logic to repeatable deployment.

Peers frame the read. Nel ASA and Plug Power sit in the same electrolyser and hydrogen equipment conversation, but ITM has been the stronger UK-listed performer this year. That relative strength is not a valuation argument by itself. It does tell you the market has been willing to pay for progress, and that makes any insider buy worth reading against a more demanding backdrop than usual. When a stock has already been rewarded for execution, insiders buying through a plan can be interpreted less as a rescue signal and more as a statement that management still sees enough operational runway to stay engaged.

The broader backdrop also helps explain why the market is willing to keep looking at the name. Energy transition capital has remained heavy, and hydrogen sits inside a wider industrial decarbonisation push rather than as an isolated niche. That does not guarantee success for any one company, but it does mean ITM is operating in a market where policy support and project development are still active. For investors, the key question is not whether hydrogen is fashionable. It is whether ITM can convert a favorable capital cycle into durable commercial traction before sentiment cools.

Three directors bought, and the scheme tells you something

On 21 August 2026, ITM disclosed purchases and matching share awards under its Buy as You Earn Share Incentive Plan by three executive directors, all executed on 14 August at £1.103 per share on AIM. Dennis Schulz, the chief executive officer, acquired 272 shares total. Simon Bourne, the chief technology officer, acquired 272 shares total. Amy Grey, the chief financial officer, acquired 814 shares total, with the larger figure reflecting a three-month contribution upon joining the scheme.

The euro-normalised filing values are small, and that is the point. Dennis Schulz’s purchase was EUR 350.84, Simon Bourne’s was EUR 350.84, and Amy Grey’s was EUR 1,049.94. On a market value of about EUR 835.3 million, these are tiny amounts. They do not change the capital structure. They do not move the balance sheet. They do, however, show that the board and executive layer were willing to buy into the plan at the same time, at the same price, after a strong share run. In a company where the market is already paying attention to execution, synchronized participation from the top team is more informative than a lone filing from a peripheral director.

InsiderTrades data gives that pattern some context. The score rationale here leans on a chief executive filing, a cluster of multiple insiders trading the same name within a month, a small or mid-cap market value band, and a filing value near EUR 351 for the CEO. That is a useful screen, not a verdict. The reason it matters is simple enough. In smaller names, insider activity has historically been less efficiently priced than in the megacaps where every move gets arbitraged to death in minutes. The market may still overreact to the signal, but it also may underappreciate the information content when the filing comes from the operating leadership rather than from a passive holder.

The structure of the plan matters as much as the fact of the purchase. Buy as You Earn schemes are not the same as a discretionary open-market buy made with spare cash after a weak trading update. They can reflect payroll timing, scheme mechanics, and routine participation. That means the filing should not be read as a dramatic all-in bet. But it also should not be dismissed as meaningless. When three executive directors participate at the same time, the message is less about conviction in a single day and more about alignment with the company’s equity story while the stock is already elevated.

What the cluster says when the stock has already run

The cluster is not the whole story, but it is the part that keeps this from being a routine payroll-plan footnote. InsiderTrades data shows 12 recent declarations and 4 distinct insiders in the cluster picture. The repeated buys by the chief executive, the chief technology officer, and the chief financial officer suggest the activity was not isolated to one person with a personal view. It was spread across the top of the operating team. That matters because it reduces the chance that the filing is just one executive’s idiosyncratic preference and increases the chance that it reflects a broader internal willingness to stay exposed to the equity.

That matters more when the stock has already gone up. A director buy after a drawdown is easy to romanticize. A director buy after a 70 percent year-to-date move is harder to dismiss as a reflexive bargain hunt. The market has already rewarded the name for policy support, project milestones, and hydrogen optimism. So the question becomes whether management still sees enough runway to keep adding, even if the amounts are modest and the mechanism is a share plan. In that sense, the cluster is useful because it sits at the intersection of price momentum and internal behavior. It does not prove upside, but it does suggest the people closest to the business are not stepping back just because the shares have rerated.

The cluster also needs to be interpreted with discipline. The recent declarations count is not a large sample in statistical terms, and the distinct-insider count is only four. That is enough to show breadth, but not enough to support sweeping conclusions about future returns. The same is true of the repeated filings by the same names. They can indicate ongoing participation, but they can also reflect the mechanics of a plan that operates over time. The right conclusion is narrower: the filing cluster is supportive of the stock’s current narrative, not determinative of it.

There is also a behavioral angle here. When a company is in the middle of a rerating, insiders buying through a plan can help reassure the market that management is not treating the move as purely external enthusiasm. That reassurance has value, especially in a sector where investors often worry that policy support is doing too much of the work. But reassurance is not the same as proof. The proof still has to come from project delivery, manufacturing execution, and the ability to turn grants and milestones into a more durable commercial profile.

The cohort bucket is decent, not magical

InsiderTrades data on chief-executive buys at sweet-spot names, defined here as EUR 300 million to 1 billion market cap companies, gives a 90-day win rate of 51.9 percent across 2,278 observations, with an average 90-day return of 6.16 percent and an average 365-day return of 59.99 percent. That is historical cohort data for a role-and-size bucket. It is not a forecast for ITM Power, and it is not a promise that this filing will work. The sample is large enough to be interesting, but not so clean that it can be treated as a law of nature. Outcomes are dispersed, and the average hides a wide range of individual paths.

The value of that cohort read is narrower and more practical. It tells you that CEO buying in this size band has not been random noise in our sample. It has had some edge over time, especially when the role is the chief executive and the company is not too large for the market to ignore the signal. But the spread of outcomes is wide, and the current stock already carries a lot of good news. If you are looking for a clean statistical edge, this is not one. If you are looking for a reason to keep the name on a short list, it is enough to matter. The statistic is most useful as a context setter, not as a trading rule.

The 365-day average return in the cohort is much stronger than the 90-day figure, which is a reminder that the market often takes time to digest insider signals in this part of the universe. That does not mean every buy needs a year to work. It does mean the immediate reaction is not always the full story. For ITM, that is relevant because the company is still in a build-out phase where operational milestones may matter more than quarter-to-quarter noise. If the business keeps advancing, the market may continue to reward the name beyond the first few weeks after the filing.

Still, the cohort data should be treated with caution because it is aggregated across many different situations. Some chief executives buy because they see a turning point in fundamentals. Others buy because they are participating in a plan. Some companies are early in a rerating, while others are already fully valued on hope. ITM sits in a market where optimism is already visible in the share price, so the historical average return is best understood as a backdrop, not a target.

The fundamentals are still the filter under the filing

InsiderTrades data puts the company’s fundamental score at 15, with a rank of 27,443 out of 28,679. The underlying pillar values are 21 for value and 9 for quality, with growth not provided. That is not a flattering screen. It says the business still looks challenged on the kind of broad fundamental ranking that rewards cleaner profitability and stronger balance-sheet optics. In other words, the market is not buying ITM because it screens as a classic quality compounder. It is buying the possibility that the company can become more than its current score suggests.

That is where the insider read has to stay honest. A director buy does not erase a weak fundamental profile. It does not turn a capital-intensive industrial into a cash machine overnight. What it can do is tell you that the people running the company are still willing to own more stock while the market is paying attention. In a name like ITM, where the equity has already rerated on policy support and project progress, that is a more interesting fact than the raw size of the purchase. The market is effectively asking whether the business can improve faster than the score implies.

The stock’s own move also matters because it changes the burden of proof. At 106 to 109 GBX, with year-to-date gains above 70 percent, the market is no longer asking whether hydrogen is a theme. It is asking whether ITM can convert theme into repeatable commercial traction. The grant, the German delivery, and the insider cluster all sit inside that question. None of them answers it alone. Together, they suggest a company that is still in the middle of proving the model rather than one that has already proven it.

The fundamental weakness also explains why the market may remain volatile even if the operational story keeps improving. A low score and low quality pillar mean investors are still being asked to tolerate uncertainty around profitability and execution. That uncertainty is common in capital-intensive transition names, but it becomes more visible after a strong share run. The higher the stock climbs, the more the market will demand evidence that the company can sustain momentum without relying solely on sector enthusiasm or policy headlines.

What could break the case from here

The obvious risk is that hydrogen remains a policy-backed market with uneven project timing. A grant can help manufacturing scale, but it does not force customers to sign orders on your timetable. A first delivery is useful, but it is still one project milestone. If project finance slows or if the sector’s capital intensity keeps biting, the share price can give back a lot of the recent enthusiasm very quickly. That is especially true when the stock has already moved sharply and expectations are elevated.

There is also the issue of scale. The insider amounts here are tiny relative to market value, and the transactions came through a share incentive plan. That means you should not read them as a large discretionary bet. The CEO, CTO, and CFO all bought, which is better than one lonely filing, but the size still says participation more than aggression. That distinction matters when a stock has already had a strong run and the market is looking for proof, not symbolism. The filing is supportive, but it is not a substitute for operating delivery.

Another risk is that the market may already be discounting too much of the good news. The shares have outperformed strongly, the company has secured grant support, and it has delivered first hydrogen from a German project. Those are all positives, but they also raise the bar for the next update. If the company cannot keep producing visible milestones, the stock may struggle to justify its current level. In that sense, the insider buying is useful because it suggests management is still willing to own the story at a higher price, but it does not remove the need for fresh evidence.

The most useful way to frame the filing is as a check on sentiment. Management is not stepping away from the stock. It is adding, in a small way, while the company is still landing grants and project milestones. If you want a cleaner tell, watch whether the next set of operational updates shows more than one-off progress. If you want the market read, watch whether the shares can hold the 106 to 109 GBX area while the hydrogen tape stays constructive and comparable names like Nel ASA and Plug Power keep trading as a sector rather than as isolated stories. The setup is constructive, but only if the business keeps converting policy support into commercial proof.

This is not investment advice.